title: Dyselectrolytemias after single dose of pamidronate administration.
abstract: Bisphosphonate such as pamidronate initially described for the treatment of neoplastic hypercalcemia, currently is being used off label to treat sever hypercalcemia of any etiology. Multiple dyselectrolytemias are a potential adverse effect of this drug, and are considered infrequent. We describe a case of transient electrolyte abnormalities after single dose of 60 mg intravenous pamidronate.
authors.affiliation: Rapid City Regional Hospital, Rapid City, SD, USA. kesu7np@yahoo.com
authors.forename: K
authors.initials: K
authors.lastname: Panday
authors.forename: R
authors.initials: R
authors.lastname: Kanth
mesh_terms: D000328:Adult; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D000077268:Pamidronate; D014883:Water-Electrolyte Imbalance / Q000139:chemically induced*
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077268:Pamidronate